The current financial score of Lipocine Inc is 6.18. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 190.10K, representing a year-over-year decrease of 69.48%, while its net profit experienced a year-over-year decrease of 18.90%.
The current valuation score of Lipocine Inc is 7.47. Its current P/E ratio is -1.13, which is -299264.15% below the recent high of 3391.03 and -876.67% above the recent low of -11.07.
The current earnings forecast score of Lipocine Inc is 7.00. The average price target is 6.00, with a high of 6.00 and a low of 6.00.
The current price momentum score of Lipocine Inc is 4.29. Currently, the stock price is trading between the resistance level at 2.46 and the support level at 2.01, making it suitable for range-bound swing trading.
The current institutional shareholding score of Lipocine Inc is 3.00. The latest institutional shareholding proportion is 25.27%, representing a quarter-over-quarter increase of 35.40%.
The current risk assessment score of Lipocine Inc is 2.79. The company's beta value is 1.10. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.